HighCape Capital

HighCape Partners Management, L.P. is a venture capital firm based in Baltimore, Maryland, with an additional office in New York, New York. Founded in 2013, the firm specializes in growth equity investments in commercial-stage life science companies that are in the early stages of revenue generation or product launch. HighCape focuses on firms that offer high-margin life science products and have a clear path to commercialization, aiming to transform them into scalable commercial entities. The firm primarily targets sectors such as healthcare devices, pharmaceuticals, and biotechnology. HighCape is a Registered Investment Adviser and manages multiple funds to support its investment strategies.

Jennifer Barretta

Partner

Charles Hart

Operating Partner

Kevin Rakin

Co-Founder & Partner

Carol Reed

Operating Partner

Dean Tozer

Partner

Matt Zuga

Partner

Past deals in Connecticut

Wellinks

Series C in 2021
Wellinks is a medical technology company that specializes in the design and development of medical devices aimed at improving respiratory health. Founded in 2014 and headquartered in Fairfield, Connecticut, the company offers innovative solutions, including Flyp, a handheld nebulizer specifically designed for patients with respiratory diseases. Wellinks operates within the health and wellness sector, focusing on enhancing the quality of care for individuals suffering from such conditions.

Cybrexa, Inc.

Series B in 2021
Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Alphina Therapeutics

Venture Round in 2020
Alphina Therapeutics is a biotechnology company that aims to leverage proprietary biomarkers and breakthrough insights for cancer patients. Its focus is on leveraging the synthetic lethal context of certain cancer patient subsets that have NAD Metabolic Deficiencies (NMD) through the development of companion diagnostics. Their goal is to develop best-in-class targeted therapies against the NAD pathway nodes in patients whose cancers exhibit hallmarks of NMD and rapidly translate these into the clinic.

Flyp Nebulizer

Series B in 2019
Flyp Nebulizer, the medical device is reinvented by Weblinks for respiratory care around the people who need it most. It works at ultrasonic speed to create a fine aerosol of medication. Flyp Nebulizer works quickly to deliver treatment within 7-minute average.

Wellinks

Series B in 2019
Wellinks is a medical technology company that specializes in the design and development of medical devices aimed at improving respiratory health. Founded in 2014 and headquartered in Fairfield, Connecticut, the company offers innovative solutions, including Flyp, a handheld nebulizer specifically designed for patients with respiratory diseases. Wellinks operates within the health and wellness sector, focusing on enhancing the quality of care for individuals suffering from such conditions.

Cybrexa, Inc.

Series B in 2019
Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.

Cybrexa, Inc.

Series B in 2017
Cybrexa, Inc. develops DNA repair inhibitors for radio- and chemo-sensitizers in cancer therapeutics. The product consists of peptide-based technology that directly targets tumor microenvironment. Cybrexa, Inc. was formerly known as Cybrexa, Inc. The company was founded in 2016 and is based in New Haven, Connecticut.